Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VERVE-102 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 2: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 3: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 4: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 5: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 6: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 7: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 8: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 9: Single Fixed Dose | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 10: Single Fixed Dose | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Name | Type | Description |
|---|---|---|
| VERVE-102 | DRUG | Intravenous (IV) infusion |
Inclusion Criteria: * Diagnosis of HeFH or premature CAD Exclusion Criteria: * Homozygous familial hypercholesterolemia * Active or history of chronic liver disease * Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe * Clinically significant or abnormal laborato...
VERVE-102 is an investigational small molecule being developed for heterozygous familial hypercholesterolemia, a genetic condition causing high cholesterol. It is also being studied in patients with premature coronary artery disease. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
VERVE-102 targets PCSK9, a protein that regulates cholesterol levels in the blood. By targeting PCSK9, the drug aims to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia. The drug is in Phase 1 clinical trials, and its mechanism of action is being evaluated in the ongoing study.
VERVE-102 is being developed by Verve Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol VERV. The company is conducting a Phase 1 clinical trial of VERVE-102 in patients with familial hypercholesterolemia or premature coronary artery disease.
VERVE-102 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is recruiting participants to evaluate the safety and tolerability of VERVE-102 in patients with heterozygous familial hypercholesterolemia.
VERVE-102 is being studied in a Phase 1 clinical trial registered as NCT06164730. This trial is recruiting an estimated 85 participants with heterozygous familial hypercholesterolemia or premature coronary artery disease. The study is being conducted in the United States, Australia, Canada, Israel, New Zealand, and the United Kingdom.